Edwards Lifesciences (EW)
Health Care · Structural heart devices and therapies
Global leader in transcatheter heart valve therapies and structural heart repair technologies, treating the world's leading cause of death with minimally invasive solutions.
What Edwards Lifesciences does
Edwards Lifesciences is a global structural heart innovation company specializing in breakthrough surgical and transcatheter therapies for valvular and non-valvular structural heart disease. The company develops and commercializes repair and replacement technologies for aortic, mitral, tricuspid, and pulmonic heart valves, serving patients with severe aortic stenosis, regurgitation, and heart failure across surgical and catheter-based treatment modalities. With over six decades of industry leadership, Edwards combines transformative product innovation with extensive clinical evidence and physician partnerships to improve patient outcomes and expand access to treatment across diverse risk profiles.
Themes: ["Cardiovascular disease treatment","Transcatheter valve therapies","Minimally invasive cardiac interventions","Structural heart disease","Heart failure management","Valve repair and replacement","Catheter-based procedures","Clinical evidence-driven innovation","Aging population health needs","Advanced medical devices"]
Fundamentals
- Price$91.33 as of 2026-07-09 close
- Market cap$53.1B as of 2026-07-10
- 1-year return+22.6% as of 2026-07-09 close
- P/E48.46 as of 2026-07-10
- Net margin+17.4% as of 2026-07-10
- Gross margin+77.9% as of 2026-07-10
- ROE+10.6% as of 2026-07-10
- Debt / equity0.06 as of 2026-07-10
- Revenue growth (YoY)+13.8% as of 2026-07-10
- Revenue CAGR (3y)+10.8% SEC XBRL
- Beta0.83 as of 2026-07-10
Key risks (from latest filing)
["Dependence on successful innovation, clinical trial outcomes, and regulatory approvals for new TAVR and structural heart products; unsuccessful procedures or clinical data could limit market adoption and growth","Manufacturing, logistics, quality control, and supply chain disruptions could impact product availability and patient access; reliance on vendors and third-party suppliers exposes the company to operational risks","Intense competition, industry consolidation, and reimbursement pressures; inability to obtain or maintain adequate governmental reimbursement rates could reduce demand and revenues"]
Competitors & peers
- Boston Scientific
- Abbott
- Medtronic
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.